Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Clinical Therapeutics|June 6, 2006
Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month studyFiona Dunbar, Young Zhu, H Robert BrashearThe American Journal of Psychiatry|May 4, 2004
Growth and sexual maturation during long-term treatment with risperidoneFiona Dunbar, Vivek Kusumakar, Denis Daneman, et al.Scientific Reports|November 6, 2025
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adultsAnna O Ermakova, Fiona Dunbar, Mathieu Seynaeve, et al.Journal of Psychopharmacology (Oxford, England)|October 20, 2021
A narrative synthesis of research with 5-MeO-DMTAnna O Ermakova, Fiona Dunbar, James Rucker, et al.Journal of Autism and Developmental Disorders|October 5, 2006
Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trialGahan J Pandina, Cynthia A Bossie, Eriene Youssef, et al.The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|March 29, 2022
Working With Lesbian, Gay, Bisexual, and Transgender Clients: Occupational Therapy Practitioners' Knowledge, Skills, and AttitudesDeborah J Bolding, Angela Acosta, Brigitte Butler, et al.Pediatrics|October 20, 2004
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disordersSarah Shea, Atilla Turgay, Alan Carroll, et al.Journal of Psychopharmacology (Oxford, England)|February 27, 2026
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine) in patients with treatment-resistant depressionClaire Roberts, Mathieu Seynaeve, Anna O Ermakova, et al.Journal of Psychopharmacology (Oxford, England)|April 15, 2024
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine benzoate) in healthy participantsJames Jonathan Rucker, Claire Roberts, Mathieu Seynaeve, et al.Headache|September 20, 2024
Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose studyJames Rucker, Matt Butler, Sadie Hambleton, et al.Pageof 2